DelveInsight’s, “Gastric Cancer Pipeline Insight 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive Gastric Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Gastric Cancer Pipeline Outlook
Key Takeaways from the Gastric Cancer Pipeline Report
- In September 2024:- Jazz Pharmaceuticals- A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA). This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- In September 2024:- Ono Pharmaceutical Co. Ltd- A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab, Fluoropyrimidine-based and Platinum-based Chemotherapy (Hereinafter Referred to as "Chemotherapy") Versus Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- August 2024:- Bold Therapeutics, Inc.- BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
- August 2024:- AstraZeneca- A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
- DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Gastric Cancer treatment.
- The leading Gastric Cancer Companies such as Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
- Promising Gastric Cancer Therapies such as Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others.
Dive into our Gastric Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Gastric Cancer Treatment Therapies
Gastric Cancer Emerging Drugs Profile
- Catumaxomab: Linton Pharm Co. Ltd.
Catumaxomab is a bispecific monoclonal antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects. It is co-developed by Trion Pharma and Neovii Biotech. Currently it is in Phase III stage of clinical trial evaluation to treat Gastric Cancer.
- HLX10: Shanghai Henlius Biotech
HLX10, a novel recombinant humanized anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius. The drug candidate works on programmed cell death-1 receptor antagonists and T lymphocyte stimulant mechanism of action. Currently being evaluated in the Phase III studies.
- FLX475: RAPT Therapeutics
FLX475 is an oral, small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body. It is in collaboration agreement with Hanmi for specific regions like Korea, Taiwan and China. Currently the drug is being evaluated in Phase II for the treatment of Gastric Cancer.
- Savolitinib: AstraZeneca/HUTCHMED
Savolitinib is an oral, potent and highly selective MET tryokinase inhibitors (TKI). It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. The drug is been developed under global licensing and collaboration agreement with AstraZeneca. The drug is in Phase II stage of clinical trials.
- ASP 2138: Astellas Pharma
ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip route. The drug candidate is being developed based on XmAb technology. The drug is under clinical development by Xencor and currently drug is in Phase I stage of clinical trials for the treatment of gastric cancer.
- Minnelide : Minneamrita Therapeutics LLC
Minnelide is under clinical development by Minneamrita Therapeutics. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). Currently being investigated in a Phase I clinical trial in patients suffering with gastric cancer.
Download the Gastric Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Gastric Cancer Clinical Trials Assessment
Gastric Cancer Therapeutics Assessment
There are approx. 180+ key companies which are developing the therapies for Gastric Cancer. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.
DelveInsight’s Gastric Cancer pipeline report covers around 200+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Dive into our detailed Gastric Cancer Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Gastric Cancer Products, Companies, and Unmet Needs
Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Gastric Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Gain valuable insights into emerging therapies and innovations with our Gastric Cancer Pipeline Report @ Gastric Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views
Scope of the Gastric Cancer Pipeline Report
- Coverage- Global
- Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Gastric Cancer Companies- Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
- Gastric Cancer Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others.
Table of Content
- Introduction
- Executive Summary
- Gastric Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- Catumaxomab : Neovii Biotech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- FLX475: RAPT Therapeutics
- Early Stage Products (Phase I)
- Comparative Analysis
- ASP 2138: Astellas Pharma
- Inactive Products
- Gastric Cancer Key Companies
- Gastric Cancer Key Products
- Gastric Cancer - Unmet Needs
- Gastric Cancer - Market Drivers and Barriers
- Gastric Cancer - Future Perspectives and Conclusion
- Gastric Cancer Analyst Views
- Gastric Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
